IRMD vs. PLSE, UTMD, TELA, APYX, ICAD, UFPT, LMAT, ATEC, MDXG, and ATRC
Should you be buying Iradimed stock or one of its competitors? The main competitors of Iradimed include Pulse Biosciences (PLSE), Utah Medical Products (UTMD), TELA Bio (TELA), Apyx Medical (APYX), iCAD (ICAD), UFP Technologies (UFPT), LeMaitre Vascular (LMAT), Alphatec (ATEC), MiMedx Group (MDXG), and AtriCure (ATRC). These companies are all part of the "surgical & medical instruments" industry.
Pulse Biosciences (NASDAQ:PLSE) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
In the previous week, Pulse Biosciences had 7 more articles in the media than Iradimed. MarketBeat recorded 10 mentions for Pulse Biosciences and 3 mentions for Iradimed. Pulse Biosciences' average media sentiment score of 1.59 beat Iradimed's score of 1.14 indicating that Iradimed is being referred to more favorably in the news media.
Pulse Biosciences has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 71.5% of Pulse Biosciences shares are owned by company insiders. Comparatively, 42.6% of Iradimed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Iradimed has a consensus price target of $62.50, indicating a potential upside of 46.03%. Given Pulse Biosciences' higher possible upside, analysts clearly believe Iradimed is more favorable than Pulse Biosciences.
Iradimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Iradimed has a net margin of 26.48% compared to Iradimed's net margin of 0.00%. Pulse Biosciences' return on equity of 24.63% beat Iradimed's return on equity.
Iradimed received 4 more outperform votes than Pulse Biosciences when rated by MarketBeat users. However, 65.17% of users gave Pulse Biosciences an outperform vote while only 64.69% of users gave Iradimed an outperform vote.
Summary
Iradimed beats Pulse Biosciences on 12 of the 17 factors compared between the two stocks.
Get Iradimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iradimed Competitors List
Related Companies and Tools
